|
Michael Kranda has served as a director since 2005. Since September, 2007 he has served as Chairman of the Board. Mr. Kranda led life sciences venture investments as Managing Director for Vulcan Capital through 2006 and continues to consult for Vulcan. He sits on the board of directors of several companies including BiPar Sciences and PTC Therapeutics. Mr. Kranda was the CEO of Oxford GlycoSciences (OGS) for six years, establishing the company as the leading proteomics platform-based drug discovery company. Prior to that, Michael spent 12 years at Immunex (now Amgen) where he served as president and chief operating officer. At Immunex, Mr. Kranda was responsible for sales and marketing, manufacturing and operations. Mr. Kranda holds a BA and an MBA from the University of Washington School of Business. | 